Sarepta Therapeutics is a biotechnology company focused on engineering precision genetic medicine to develop treatments for rare diseases. It engages in drug development and gene therapy manufacturing.

Sarepta Therapeutics

Domain Not Resolving

Amazon

DMARC

Microsoft Azure DNS

Amazon Virginia Region

Amazon S3 CDN

Mimecast

ASP.NET 2.0

Symantec.cloud

Executive Vice President, Chief People Officer

Alison Nasisi

Chief Information Officer

Bill Thornton

Senior Vice President, Corporate Transactions; Deputy General Counsel

Cris Rothfuss

Executive Vice President, Head of R&D and Chief Scientific Officer

Louise Rodino-Klapac

Operations

Nixon Luc

Director, Analytical and Quality Control Raw Material and CMO Management

Princess Hernandez-Wilson

Executive Vice President, Chief General Counsel

Ryan E. Brown

Executive Director, Late-Stage Program Management

Walter Kehoe

EVP, Chief Technical Operations Officer

Bilal Arif

Executive Vice President, Technical Operations

Bill Ciambrone

Douglas S Ingram

CEO & President

Sandy Mahatme

Chief Financial Officer, Chief Business Officer

Jayant Aphale

Senior Vice President of Technical Operations

Alex Lagadinos

Associate Director, Corporate Development

James Summerton

Founder

Peter Montague

Director Of Facilities

Kathy Behrens Wilsey

Director

Gary Charbonneau

SVP, GM , Head of Research & Early Development

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.

Myonexus Therapeutics is a clinical stage gene therapy company developing first ever treatments for Limb-girdle muscular dystrophy  types.

Massachusetts Therapeutics Companies

Massachusetts Health Care Companies

Investors Active in Research Triangle

Health Care Companies With More Than $10M in Revenue (Top 10K)

Sarepta Therapeutics is a biopharmaceutical company that focuses on the discovery and development of precision genetic medicine to treat rare diseases. It specializes in gene therapy, RNA-targeted exon skipping, and gene editing.

It was founded in 1980 and headquartered in Cambridge, Massachusetts.

Michael Andrew Chambers

Post-IPO Equity - Sarepta Therapeutics

Pharmakon Advisors

Post-IPO Debt - Sarepta Therapeutics

MidCap Financial

Cambridge

Massachusetts

United States

North America

Arrowhead climbs after licensing deal with Sarepta

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?

Sector Update: Health Care Stocks Advance Tuesday Afternoon

Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta

Sector Update: Health Care

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

H.C. Wainwright Starts Sarepta Therapeutics (SRPT) at Sell

Sarepta Therapeutics develops gene therapies aimed at treating Duchenne muscular dystrophy by delivering functional copies of the dystrophin gene to muscle cells.

Sarepta's RNA technologies focus on exon-skipping therapies for Duchenne muscular dystrophy, using PMO and PPMO chemistries to enhance treatment efficacy.

Sarepta is developing gene therapies targeting specific genetic defects in various subtypes of limb-girdle muscular dystrophy to restore muscle function.

Sarepta is exploring gene therapies for Charcot-Marie-Tooth disease, focusing on correcting genetic defects affecting peripheral nerves.

A patient support program providing information and assistance for starting and maintaining therapy for Sarepta's treatments in the United States.

United Kingdom

Europe

Italy

Poland

India

Asia

HTML5

Google Tag Manager

DigiCert

Office 365

HubSpot Marketing Hub

Amazon EC2

Symantec Email Security.Cloud

Microsoft Outlook

Google Analytics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Dec 6, 2024 3:05 AM	d816f1e8
public peers	general	Oct 2, 2024 1:19 PM	d3387367
news daily refresh	general	Dec 4, 2024 2:16 PM	e574a455
news processing daily refresh	general	Dec 5, 2024 5:11 AM	3d187654
news impact assignment daily	general
news processing basic	general	Dec 5, 2024 5:10 AM	8849d46b
company summary	general
signals	general	Oct 2, 2024 1:19 PM	d866a2b8
crunchbase trigger	general	Nov 27, 2024 12:50 PM	37be8959
crunchbase profile	general	Nov 27, 2024 1:25 PM	f17e684f
li profile	general
translate crunchbase fundingrounds	general	Nov 27, 2024 3:00 PM	0aa7a446
peers	general	Oct 2, 2024 1:19 PM	e85e5770
news basic	general	Dec 4, 2024 2:13 PM	4d644484
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SAREPTA

Sarepta Therapeutics

Last Close

110.50

22/11 21:00

Market Cap

14.11B

Beta: -

Volume Today

913.72K

Avg: -